Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy

Abstract excerpt

<title>Abstract</title> <p>RAS oncogenes (collectively <italic>NRAS</italic>, <italic>HRAS</italic>, and especially <italic>KRAS</italic>) are among the most frequently mutated genes in cancer, with common driver mutations occurring at codons 12, 13 and 61¹. Small molecule inhibitors of the KRAS^G12C oncoprotein have demonstrated clinical efficacy in patients with multiple cancer types and ha...

Topics

Open a Topic to create a Post that cites this publication.

• Antineoplastic Agents
• GTP Phosphohydrolases
• Guanosine Triphosphate
• Mice, Inbred BALB C
• Oncogene Protein p21(ras)
• Piperazines
• Proto-Oncogene Proteins p21(ras)
• Xenograft Model Antitumor Assays

Identifiers and source

Literature Corpus work

298a4533-5075-5af2-9191-059c7e2bfd7a

DOI

10.21203/rs.3.rs-3122478/v1